Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

Bride Morgan Hafeman upcycled her leftover wedding dress scraps into two purses. 'What I love most about my wedding keepsakes ...

Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, following the Q4 report. The firm awaits the Phase 3 ...

Goldman Sachs US Biotechnology Analyst Salveen Richter explains on "Bloomberg Markets." UK could face Trump VAT tariff hit; pound hits 2025 high – business live 7 reasons why you feel tired all ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Good day, and thank you for standing by. Welcome to the Moderna fourth quarter 2024 conference call. (Operator Instructions) Please be advised ...

Goldman Sachs analyst Salveen Richter initiated coverage of the company’s stock with a “Buy” rating and a price objective of $42. As per the analyst, Summit Therapeutics Inc. (NASDAQ ...

In addition to Mizuho Securities, Apellis Pharmaceuticals also received a Hold from Goldman Sachs’s Salveen Richter in a report issued on March 3. However, on March 5, UBS maintained a Buy ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Good day, and thank you for standing by. Welcome to the Moderna fourth quarter 2024 conference call. (Operator Instructions) Please be advised, ...

Salveen Richter, Goldman Sachs: Inquired about BLU-808’s safety profile and potential dosing strategies. CMO Becker Hewes noted the drug’s wide therapeutic index and plans to test various ...

What Else: Goldman Sachs analyst Salveen Richter recently downgraded Moderna from Buy to Neutral and lowered the price target from $99 to $51, citing lower conviction following a second product ...